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(CF), a genetic disease caused by mutations in the CFTR gene, is a
life-limiting disease characterized by chronic bacterial airway infec-
tion and severe inflammation. Some CFTR mutants have reduced
responsiveness to cAMP/PKA signaling; hence, pharmacological
agents that elevate intracellular cAMP are potentially useful for the
treatment of CF. By inhibiting cAMP breakdown, phosphodiesterase
(PDE) inhibitors stimulate CFTR in vitro and in vivo. Here, we
demonstrate that PDE inhibition by RPL554, a drug that has been
shown to cause bronchodilation in asthma and chronic obstructive
pulmonary disease (COPD) patients, stimulates CFTR-dependent ion
secretion across bronchial epithelial cells isolated from patients car-
rying the R117H/F508del CF genotype. RPL554-induced CFTR ac-
tivity was further increased by the potentiator VX-770, suggesting an
additional benefit by the drug combination. RPL554 also increased
cilia beat frequency in primary human bronchial epithelial cells. The
results indicate RPL554 may increase mucociliary clearance through
stimulation of CFTR and increasing ciliary beat frequency and thus
could provide a novel therapeutic option for CF.
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THE COMMON, AUTOSOMAL RECESSIVE disease cystic fibrosis (CF)
results from mutations to the gene encoding cystic fibrosis
transmembrane conductance regulator (CFTR) (52), a plasma
membrane anion channel. Defective CFTR-dependent anion
transport leads to a host of pathologies that affect the pancreas,
small intestine, sweat glands, and airways (5, 34, 35, 49, 50,
64). In the airways, reduced secretion contributes to the accu-
mulation of thick, sticky mucus and impaired mucociliary
clearance, which in turn leads to bacterial colonization and
chronic inflammation (41, 60). CFTR is tightly regulated by the
cAMP/PKA signaling pathway (3, 12, 13, 17, 27, 54, 61), and
therefore, pharmacological agents that elevate intracellular
cAMP concentration ([cAMP]i) have been suggested as poten-
tial therapeutic options for the treatment of CF (31). Cyclic
nucleotide phosphodiesterases (PDEs) terminate signaling by
hydrolyzing cyclic nucleotides (7). The PDE superfamily in-
cludes 11 gene families and over 30 isozymes, each with
multiple splice variants that together comprise almost 100
different variants (42). Expression and localization of PDE
isoenzymes are cell and tissue specific, and many PDEs are
often expressed in specific microdomains that allow for highly
organized spatiotemporal cyclic nucleotide signaling. For de-
tailed reviews of PDEs, see Conti and Beavo (14), Francis et al.
(21), and Maurice et al. (42).
PDE3 and PDE4 have been shown to regulate CFTR in
primary airway epithelial cells and in epithelial cell lines.
PDE4A5, PDE4C1, PDE4D2, and PDE4D3 expression was
demonstrated in primary human airway epithelial cells (22),
and PDE3 and PDE4 inhibitors have been shown to elevate
[cAMP]i in airway epithelia, when added alone (12) or in
combination with activators of adenylyl cyclase (22, 65).
Furthermore, both PDE3 and PDE4 inhibitors have been
shown to activate CFTR-dependent anion secretion across the
human airway epithelial cell line Calu-3 (12, 48) while Barnes
et al. (4) demonstrated increased CFTR channel activity when
apical membrane patches excised from Calu-3 cells were
exposed to a PDE4 inhibitor. CFTR can interact physically
with PDE4D (38) and PDE3A (48), and exposure to a PDE3A
inhibitor leads to clustering of CFTR and PDE3A into mem-
brane microdomains and augments CFTR channel function
(48). These results suggest that inhibitors of PDE3 and PDE4
could potentially be useful therapeutics for CF.
More recently, Blanchard et al. (6) demonstrated that the
PDE4 inhibitor rolipram, when used in combination with
CFTR potentiators and correctors, stimulates CFTR activity in
primary human bronchial epithelial (HBE) cells homozygous
for the most common CF mutation F508del (10). In addition to
their CFTR-activating properties, PDE3 and 4 inhibitors also
have beneficial anti-inflammatory and bronchodilator effects,
which would provide additional benefits to CF patients. Di
Paola et al. (19) demonstrated PDE3 inhibition significantly
reduced tissue inflammation and the release of proinflam-
matory cytokines in a rat model of myocardial inflammation
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while PDE4 inhibition has also been shown to reduce the
release of proinflammatory cytokines from a number of cell
types, including airway epithelial cells, as well as suppress-
ing recruitment of inflammatory cells to the airways (24 –26,
37, 40, 45, 68).
Of further interest, there is increasing evidence to suggest
that dual inhibition of PDE3 and PDE4 can have additive or
synergistic anti-inflammatory, bronchodilator, and CFTR- ac-
tivating effects (1, 39, 44, 48) suggesting that targeting both
PDEs may be of greater benefit than inhibiting one alone.
RPL554 is a “first in class” inhaled dual PDE3/4 inhibitor that
has significant bronchodilator and anti-inflammatory activity in
clinical trials (20). RPL554 has been demonstrated to induce
sustained relaxant effects on contractile responses induced by
spasmogens (histamine and carbachol) and electrical field stim-
ulation in isolated airway tissue (human bronchial and guinea
pig tracheal preparations). The degree of bronchial wall relax-
ation was greater than in tissue treated only with a 2-agonist
or anti-muscarinics, even when those agents were administered
at maximal concentrations (9). Interestingly, RPL554 also
interacts in an additive or synergistic manner with 2-agonists
or anti-muscarinics, respectively, when administered in com-
bination in in vitro and in vivo experimental model systems (8,
30). The fact that RPL554 inhibits PDEs involved in CFTR
regulation, as well as possessing anti-inflammatory and bron-
chodilator properties, suggests it could afford therapeutic ben-
efit in CF patients. PDE inhibitors may also act on airway cilia
since their motility is also controlled by cAMP/PKA (2, 18, 55,
63) probably through phosphorylation of dynein light chain in
the axoneme (36) Indeed, the PDE4-selective inhibitor
Roflimulast N-oxide increased ciliary beat frequency (CBF) in
HBE (43).
The purpose of this study was to examine the effect of
RPL554 on CFTR function in cell lines and primary HBE from
CF patients with R117H/F508del and F508del/F508del geno-
types. R117H reduces single channel conductance and open
probability but does not affect trafficking to the plasma mem-
brane or activation by cAMP/PKA (11, 57, 62). F508del
reduces open probability and nearly abolishes trafficking to the
plasma membrane without altering single channel conductance
(10, 15). We also examined the effect of RPL554 on ciliary
beating. Here we show that RPL554 stimulates the activity of
wild-type (WT) and R117H CFTR, and this is primarily due to
inhibition of PDE4. RPL554 also increases CBF primarily
through inhibition of PDE4. These results suggest RPL554 as
an attractive therapeutic option for CF and reveal novel mech-
anisms by which inhaled RPL554 may improve lung function
in chronic obstructive pulmonary disease (COPD) and asthma
patients.
METHODS
Culture of Chinese hamster ovary cells. The Chinese hamster ovary
cell line CHO, expressing WT CFTR (61), was cultured in minimum
essential media (MEM) containing 5% fetal bovine serum and the
selecting drug methotrexate (100 mM) for 2 days. Cells were grown
in T75 flasks (Corning), incubated at 37°C in humidified air containing
5% CO2-95% O2, and passaged every 7 days using trypsin/EDTA. For
automated patch-clamp experiment, CHO were subcultured in 25-cm2
plates and used at 80% confluence (1 million cells).
Culture of CFBE cells. The HBE cell line CFBE was cultured in
MEM supplemented with 10% (vol/vol) FCS, 100 U/ml penicillin,
100 g/ml streptomycin, and 2 g/ml puromycin as a selection agent.
Cells were grown in T75 flasks (Corning), incubated at 37°C in
humidified air containing 5% CO2-95% O2, and passaged every 7
days using trypsin/EDTA. 80,000 cells were seeded onto collagen-
coated 6.5-mm Corning Costar 0.4-m pore, polyester membrane
inserts and kept submerged 48 h until cells had formed a highly
resistive monolayer with transepithelial electrical resistance (TEER)
400 /cm2 as measured using an epithelial volt-ohmmeter (World
Precision Instruments). The apical medium was then removed and
cells were maintained at the air-liquid interface (ALI) for another 7
days before being studied.
Isolation and culture of primary HBE cells. Human lung tissues
were procured under the auspices of Institutional Review Board-
approved protocols at McGill University and the University of North
Carolina. Three lung specimens unused for transplantation were
obtained from non-CF individuals, and three F508del/F508del spec-
imens and three R117H/F508del specimens were procured after lung
transplantation. The non-CF and F508del/F508del cells were from the
CF Canada Primary Airway Cell Biobank at the McGill CF Transla-
tional Research Centre (CFTRc). R117H/F508del cells were from the
Univeristy of North Carolina CF Center Tissue Procurement and Cell
Culture Core. Isolation, culture, and differentiation of pHBE cells
were adapted from procedures previously described by Fulcher et al.
(23). Briefly, airway epithelial cells were isolated from bronchial
tissue by enzyme digestion and cultured in bronchial epithelial growth
medium on type I collagen-coated plastic flasks (Vitrogen 100, Pure-
Col; Advanced BioMatrix) and then trypsinized, counted, and cryo-
preserved. Cells were seeded onto collagen coated 6.5-mm Costar
0.4-m pore, polyester membrane inserts (Corning) and grown under
submerged conditions for 4 days before the apical media were re-
moved and the cells were allowed to differentiate at an ALI for a
minimum of 21 days before use. The isolation and growth media were
complemented with antibiotics selected according to recent patient
microbiology reports. However, only penicillin and streptomycin
were added to the ALI cultures.
RNA extraction and quantitative real-time PCR. Total cellular
RNA was extracted and purified using the RNase Easy Mini Kit
(Qiagen, Toronto, ON, Canada) according to the manufacturer’s
instructions. For reverse transcription, 500 ng RNA were incubated
with 4 l VILO Mastermix (Life Technologies, Burlington, ON,
Canada) in a reaction volume of 20 l for 1 h at 42°C and for 5 min
at 85°C. Then, 250 ng cDNA, 10 l TaqMan Fast Advanced Master-
mix, and 1 l TaqMan Gene Expression Assay primers were added to
the wells of a MicroAmp EnduraPlate Optical 96-Well Fast Reaction
Plate in a reaction volume of 20 l. The quantitative PCR reaction
consisted of 20 s at 95°C and then 40 cycles of 95°C (1 s) and 60°C
(20 s) and was carried out in a QuantStudio 7 Flex Real-Time PCR
system. CT analysis was carried out using QuantStudio 7 Flex
Real-Time PCR system software in which the expression of each PDE
gene was normalized to expression of GAPDH within that sample.
Analysis of the standard curves made for each primer revealed primer
efficiency to be 90% for each primer used.
Patch-clamp experiments. The effects of RPL554 on CFTR cur-
rents were measured using an automated patch-clamp technique. CHO
cells were detached with Detachin (Genlantis, San Diego, CA) cen-
trifuged for 5 min at 1,000 rpm, resuspended in MEM (without
serum), and used immediately on the Qpatch 16X system (Sophion
Bioscience). The holding potential was set to 40 mV during the
entire experiment, and two voltage protocols were used to measured
whole cell CFTR current. To control for the effect of various drug or
concentration and test the absence of leak, a single depolarization
from 40 at 0 mV was applied. After 5 min, the current/voltage (I–V)
relationship was determined by pulsing from 40 mV between 80
and 	80 mV in 20-mV increments. Experiments were conducted with
single-hole Qplate at room temperature.
Short-circuit current measurements. Primary HBE cells were
grown on collagen-coated polyester membrane inserts (6.5-mm Corn-
ing Costar 0.4-m pore) and cultured in serum- and antibiotic-free
medium with 20 l medium applied to the apical membrane 24 h
before study. Cells were mounted into modified Ussing chambers
(Physiological Instruments, San Diego, CA) containing 5 ml sa-
line, which was continuously gassed with 5% CO2-95% O2. Mono-
layers were clamped at 0 mV using a Multichannel Voltage-
Current Clamp (Physiological Instruments) and currents recorded
using a Powerlab 8SP (AD Instruments) and analyzed using
LabChart 7.0 software. Transepithelial resistance (Rte) was moni-
tored by applying a 10-mV pulse (duration: 2 s) every 30 s and
calculating resistance by Ohm’s law.
Measurements of CBF. Primary HBE cells were grown on 12-mm
collagen-coated Millicell 0.4-m pore inserts and cultures were visu-
alized using a 
20 phase objective on a Nikon TE2000 microscope,
and high-speed videos (60 fps) were recorded from 5 separate fields of
each culture. CBF was determined from the videos using the whole
field analysis option within the SAVA software package (58), and the
average of the five measurements was used as the baseline CBF for
that culture. Cultures were then treated with pharmacological agents
and CBF was again determined from the average of five measure-
ments taken 1, 5, and 30 min after treatment. Data were analyzed as
both the absolute change in CBF at each time point and the change in
CBF relative to baseline. Each experiment was repeated at least three
times with cells from three different donors (n  9).
Solutions and reagents. All reagents were purchased from Sigma-
Aldrich apart from CFTRinh 172 (Cystic Fibrosis Foundation Thera-
peutics), RPL554 (Verona Pharma, London, UK), and TNF- (R&D
Systems, Minneapolis, MN). Gases were purchased from MEGS
Speciality Gases (Montreal, Canada). For patch-clamp recordings, the
external bath solution contained the following (in mM): 145 NaCl, 4
CsCl, 1 CaCl2, 1 MgCl2, 10 glucose, and 10 tetradecyl sulfate (TES)
and titrated to pH 7.4. The intrapipette solution contained the follow-
ing (in mM): 113 L-aspartic acid, 113 CsOH, 27 CsCl, 1 NaCl, 1
MgCl2, 1 ethyleneglycoltetraacetic acid, 1 TES, and 3 MgATP and
titrated to pH 7.2. For short-circuit current (Isc) measurements, the
basolateral saline solution consisted of the following (in mM): 115
NaCl, 25 NaHCO3, 1.2 MgCl2, 1.2 CaCl2, 2.4 KH2PO4, 1.24
K2HPO4, and 10 D-glucose, while the apical saline solution consisted
of the following (in mM): 1.2 NaCl, 115 Na-gluconate, 25 NaHCO3,
1.2 MgCl2, 4 CaCl2, 2.4 KH2PO4, 1.24 K2HPO4, and 10 D-glucose.
Statistical analysis. Statistical analysis was performed using
GraphPad Prism 5 software. Student’s t-test, one-way ANOVA (with
Tukey’s multiple comparison posttest), or two-way ANOVA (with
Bonferroni posttest) was carried out where applicable to determine
statistical significance between measurements. P  0.05 was consid-
ered statistically significant.
RESULTS
RPL554 does not activate CFTR directly but potentiates
forskolin-stimulated CFTR currents in CHO cells. To first gain
insight into possible direct effects of RPL554, whole cell
currents were recorded in CHO cells expressing CFTR. No
activation was observed with RPL554 alone, indicating it does
not act directly on CFTR and does not elevate cAMP signifi-
cantly in CHO cells, which might be due to low basal flux
through the cAMP pathway or insensitivity of endogenous
PDEs to RPL554 (Fig. 1). Forskolin (10 M) stimulated
currents of 35.6  15.2 pA/pF at 	40 mV (P  0.001 vs.
unstimulated cells; n  3; Fig. 1A), which was significantly
reduced to 6.19  2.70 pA/pF by CFTRinh 172 (P  0.05; n 
3), demonstrating CFTR was active in these cells. However.
RPL554 potentiated CFTR activity when cells were stimulated
with a submaximal concentration of forskolin. Two micormo-
les of forskolin alone stimulated a CFTR-dependent current of
10.19  0.81 pA/pF at 	40 mV (n  4), and this was dose
dependently increased by RPL554, which reached statistical
significance at 0.3 M RPL554 (Fig. 1B). At the highest
concentration of RPL554 tested (10 M), CFTR-dependent
currents were 103.34  13.13 pA/pF at 	40 mV (n  13; P 
0.001 vs. forskolin alone; Fig. 1B) meaning 10 M RPL554
had potentiated forskolin-stimulated CFTR activity 10 fold.
Therefore, although RPL554 failed to stimulate CFTR activity
alone, the fact it could enhance forksolin-stimulated CFTR
activity to such an extent indicates its potential to enhance
CFTR activity.
RPL554 acts as a CFTR activator in WT CFBE cells. We
next examined whether RPL554 was able to activate WT
CFTR in the human airway epithelial cell line CFBE. RPL554
dose dependently increased CFTR-dependent Isc with the high-
est concentration of RPL554 tested (10 M) increasing Isc by
49.8  7.8 A cm2 (n  4). For comparison this was 57.6 
3.8% of the stimulation produced by a maximal (10 M) con-
centration of forskolin (86.5  12.0 A/cm2; n  5; Fig. 2).
Therefore, these data suggested that RPL554, via inhibition of
PDE3 and/or PDE4, raised [cAMP]i levels sufficiently to acti-
vate CFTR-dependent transepithelial anion secretion to levels
that are comparable with those produced by forskolin. Thus
Fig. 1. RPL554 does not stimulate cystic fibrosis
transmembrane conductance regulator (CFTR) di-
rectly but potentiates forskolin-stimulated CFTR
current in Chinese hamster ovary (CHO) cells.
CFTR-dependent currents in CHO cells express-
ing CFTR were measured using the broken patch,
whole cell patch configuration. A: CFTR-depen-
dent current obtained at 	40 mV in response to
stimulation of cells with RPL554 or forskolin
(Fsk). Data represent means  SE; P  0.001; n
 3–19. B: increase in CFTR-dependent currents
obtained at 	40 mV by increasing concentrations
of RPL554 after cells had been prestimulated with
forskolin (2 M). Data represent means  SE; *P
 0.05, **P  0.01, ***P  0.001;n  6–17.
RPL554 activates robust secretion by this human airway cell
line in the absence of other secretagogues.
PDE expression is altered in CF pHBE cells compared with
WT pHBE cells. RPL554 is a dual PDE3/4 inhibitor; therefore,
we examined the expression of these PDE isoenzymes, to-
gether with other PDE isoforms as well as examining whether
their expression was altered in CF. Expression of a subset of
eight known PDE isoforms was assessed in HBE cells from
three non-CF donors, three patients homozygous for F508del,
and three patients carrying R117H/F508del. By assessing the
relative expression of each PDE gene tested when normalizing
to the expression of GAPDH, we were able to get an indication
of which PDE genes were most abundantly expressed in HBE
cells. As shown in Fig. 3A, PDE4D was expressed in relatively
high abundance in WT cells, which is unsurprising given the
body of evidence implicating PDE4D in CFTR regulation in
human airway epithelia. However, there was a very low ex-
pression of PDE3A when normalized to GAPDH expression
across all three genotypes, indicating PDE3A is expressed at
very low levels in HBE cells relative to other PDE isoforms.
An unexpected finding was the abundance of PDE7A and
PDE8A expression in all three genotypes, raising the question
as to their role in cyclic nucleotide signaling in human airway
epithelia. When normalizing the PDE gene expression relative
to the WT patients, we observed a 5.1  2.3-fold upregulation
of PDE3A and a 3.9  1.9-fold upregulation of PDE4D in
F508del/F508del cells compared with WT (P  0.001 vs. WT;
n  3 for each; Fig. 3B), which suggests a loss of CFTR at the
cell surface may modulate expression of proteins involved in
CFTR regulation.
PDE inhibition does not stimulate CFTR-dependent trans-
epithelial ion transport in HBE F508del/F508del cells but
increases the response to VX-770. To assess whether 1)
RPL554 had similar CFTR stimulatory effects in HBE cells as
those observed in CFBE cells and 2) RPL554 was able to
potentiate the activity of mutant CFTR, the effect of RPL554
was tested in F508del/F508del HBE cells. To gain insight into
the mechanism of action, the effects of RPL554 were also
compared with those of the PDE3-selective inhibitor milrinone
and the PDE4-selective inhibitor rolipram. Cells were pre-
treated for 24 h with VX-809 (1 M) and VX-770 (100 nM) to
mimic the current treatment for F508del/F508del patients. A
submaximal concentration of forskolin (2 M) stimulated an
increase in Isc of 2.9  0.3 A cm2 (n  25; Fig. 4).
However, subsequent exposure to specific PDE inhibitors did
not further enhance Isc and actually caused a small decrease in
CFTR-dependent Isc. PDE-stimulated increases in Isc after
forskolin stimulation were 0.3  0.1, 0.3  0.1, 1.0 
0.4, and 0.1  0.1 A/cm2 by milrinone (10 M), rolipram
(10 M), milrinone 	 rolipram, and RPL554 (10 M), respec-
Fig. 2. RPL554 stimulates CFTR-dependent short-circuit current (Isc) in wild-type (WT) CFBE cells. CFBE cells expressing WT CFTR were grown at air-liquid
interface (ALI) for 7 days before Isc measurements were made in an Ussing chamber. A: example experiments in which Isc was measured in response to increasing
concentrations of RPL554 (100 nM to 10 M) and forskolin (10 M). B: summary of the data. Data represent means  SE; n numbers are displayed in
parenthesis.
Fig. 3. Phosphodiesterase (PDE) isoform expression in human bronchial
epithelial (HBE) cells. HBE cells were isolated and cultured as described in
METHODS and gene expression was assessed using quantitative PCR. A: ex-
pression of each PDE gene when normalized to the expression of GAPDH in
each sample. **P  0.01, significant difference between WT and F508del/
F508del cells. B: expression of each PDE gene, normalized to the expression
of GAPDH in each sample, and normalized to the expression levels seen in WT
cells. *P  0.05, ***P  0.001, significant difference between WT and
F508del/F508del HBE cells. Data represent means  SE; n  3 different
patients for each genotype.
tively (n  5–7; Fig. 4). These results suggest that F508del
CFTR at the membrane was fully activated by forskolin fol-
lowing rescue by the corrector VX-809 and chronic potentia-
tion by VX-770, and thus any subsequent increases in cAMP
were unable to further stimulate CFTR-dependent anion trans-
port. We also investigated whether PDE inhibition could stim-
ulate F508del CFTR in noncorrected cells (i.e., cells not
treated for 24 h with VX-809 or VX-770). In these conditions,
forskolin (2 M) stimulated a negligible increase in Isc of
0.05  0.02 A/cm2 (n  12), while subsequent stimulation of
cells with either rolipram (10 M) or RPL554 (10 M) caused
highly variable increases in Isc that were not significantly
different to DMSO controls (DMSO  0.05  0.03 A/cm2;
rolipram  0.13  0.10 A/cm2; RPL554  0.03  0.15
A/cm2; P  0.05; n  3–6; Fig. 5) These data demonstrate
that F508del CFTR does not respond to cAMP stimulation in
noncorrected cells. However, PDE inhibition was able to sig-
nificantly increase the VX-770-stimulated increase in Isc from
0.34  0.13 A/cm2 in control cells to 0.74  0.06 and
0.80  0.05 A/cm2 in rolipram and RPL554-stimulated cells,
respectively (P  0.05 vs. control; n  3–6; Fig, 5). Thus,
although ineffective at stimulating F508del CFTR alone, PDE
inhibitors can augment VX-770-dependent potentiation of
F508del CFTR suggesting that RPL554 and VX-770 in com-
bination might provide additional benefit to F508del/F508del
patients.
RPL554 stimulates CFTR-dependent transepithelial ion trans-
port in pHBE R117H/F508 cells by inhibiting PDE4. Next,
we explored the role of different PDEs in modulating the
response of CF HBE cells (R117H/F508del) to cAMP stimu-
lation. A submaximal concentration of forskolin (2 M) stim-
ulated an increase in Isc of 1.4  0.1 A/cm2 (n  16; Fig. 6).
Inhibiting basal PDE activity with either milrinone, rolipram,
milrinone 	 rolipram, or RPL554 caused negligible increases
in Isc (0.1  0.02, 0.5  0.1, 0.1  0.3, and 0.2  0.2 A/cm2,
respectively; n  3–7; Fig. 7), suggesting that PDE3 and 4
inhibition alone did not elevate [cAMP]i sufficiently to stimu-
late R117H CFTR. However, when added after exposure to a
submaximal concentration of forskolin, stimulation was ob-
served with the specific PDE4 inhibitor rolipram (0.9  0.2
A/cm2; P  0.01; n  6), a combination of specific PDE3
and PDE4 inhibitors (milrinone 	 rolipram; 0.7  0.1 A/
cm2; P  0.05; n  5), and with the dual PDE3/PDE4 inhibitor
RPL554 (0.9  0.2 A/cm2; P  0.01; n  9; Fig. 7). By
Fig. 4. PDE3/4 inhibitors do not potentiate forskolin-stimulated CFTR-dependent Isc in HBE F508del/F508del cells. F508del/F508del HBE cells were isolated
and cultured as described in METHODS and Isc measurements were made in Ussing chambers. Cells were treated with the CFTR corrector VX-809 (3 M) and
the CFTR potentiator VX-770 (100 nM) for 24 h before study. A: representative experiments in which Isc was measured in response to treatment with forskolin
(2 M) followed by either the PDE3 inhibitor milrinone (Mil; 10 M apical; top left), the PDE4 inhibitor rolipram (Rol; 10 M apical; top right), milrinone
and rolipram (Mil 	 Rol; bottom left), and RPL554 (10 M apical; bottom right). Cells were first treated with apical amiloride (Amil; 100 M) and the current
was inhibited by CFTRinh 172 (Inh 172; 10 M apical) while cells maintained functionality, demonstrated by a response to apical ATP (100 M). B: summary
of the increase in Isc in response to PDE inhibition after 2 M forskolin prestimulation. Data represent means  SE; n numbers are displayed in parenthesis.
contrast, the response to milrinone alone after submaximal
forskolin stimulation was negligible (0.03  0.1 A/cm2;
n  5; Fig. 7) indicating that PDE3 has little role in regulating
CFTR. Together, these results identify PDE4 as the primary
regulator of CFTR-dependent transepithelial ion secretion in
HBE R117H cells prestimulated with forskolin. Interestingly,
when R117H/F508del HBE cells were pretreated with VX-
809, forskolin-stimulated Isc was enhanced but not the response
to PDE inhibitors (Figs. 6 and 7). This suggests that CF cells
have diminished regulation of the cAMP microdomain sur-
rounding CFTR, which is not fully corrected by VX-809 and
may be due to alterations in both the cytoskeleton (46) and the
localization of PDE4.
PDE3 and 4 contribute to compartmentalization of cAMP
signaling in CF airway epithelia. A well-established role for
PDEs is to compartmentalize cAMP in a specific subcellular
microdomain to allow for efficient spatiotemporal cAMP sig-
naling to occur (4) although this role has been challenged with
respect to CFTR regulation (46). To investigate the role of
PDEs during global and localized elevations of cAMP, CF
(R117H/F508) HBE cells were stimulated with forskolin to
increase [cAMP] throughout the cell, or apical adenosine, to
increase cAMP preferentially in the subapical membrane mi-
crodomain. Forskolin stimulated a larger increase in CFTR-
dependent Isc (1.4  0.1 A/cm2; n  16), compared with that
induced by apical adenosine (0.2  0.2 A/cm2; P  0.001;
n  6; Fig. 8A). However, the subsequent response to PDE
inhibitors was similar in cells stimulated with either agonist.
Milrinone 	 rolipram increased Isc by 0.6  0.1 and 0.8  0.3
A/cm2 after pretreatment with forskolin and adenosine, re-
spectively (P  0.05; n  3–9; Fig. 8B), and RPL554 in-
creased Isc by 0.9  0.2 and 0.7  0.2 A/cm2, respectively
(P  0.05; n  3–9; Fig. 8B). Together, these data imply that
PDE regulation occurs predominantly in the subapical cAMP
compartment in HBE R117H/F508del cells.
VX-770 and RPL554 have additive effects on CFTR-depen-
dent anion transport. Given that we have already shown that
PDE inhibition enhances CFTR activity in R117H/F508del
HBE cells, it was interesting to test the effect of PDE inhibition
in combination with the clinically approved CFTR potentiator
VX-770 (Kalydeco). To this end, R117H/F508del cells were
stimulated with 2 M forskolin and then treated with either 10
M RPL554 followed by 100 nM VX-770 (Fig. 9A, left) or in
reverse order; i.e., 100 nM VX-770 followed by 10 M
RPL554 (Fig. 9A, right). RPL554 further increased the fors-
kolin-stimulated CFTR-dependent Isc by 2.4  0.2 A/cm2
Fig. 5. PDE3/4 inhibitors do not stimulate noncorrected F508del CFTR but can potentiate the stimulation by acute VX-770. F508del/F508del HBE cells were
isolated and cultured as described in METHODS and Isc measurements were made in Ussing chambers. A: representative experiments in which Isc was measured
in response to treatment with forskolin (2 M) followed by either DMSO (top left), the PDE4 inhibitor rolipram (10 M apical; top right), or RPL554 (10 M
apical; bottom left). The response to acute VX-770 (100 nM apical) was also assessed. Cells were first treated with apical amiloride (100 M) and the current
was inhibited by CFTRinh 172 (10 M apical) while cells maintained functionality, demonstrated by a response to apical ATP (100 M). B: summary of increase
in Isc in response to PDE inhibition after 2 M forskolin prestimulation. C: summary of the increase in Isc in response to acute VX-770. *P  0.05, **P  0.01,
significant effect of PDE inhibition vs. DMSO. Data represent means  SE; n  3 for DMSO and rolipram and n  6 for RPL554.
(n  4), and the subsequent addition of VX-770 caused a
further increase of 6.2  0.3 A/cm2. The net increase in
CFTR-dependent Isc under these conditions (8.6  0.6 A/
cm2) was significantly greater than when either agonist was
added alone (P  0.01; n  3; Fig. 9B). Adding VX-770 after
forskolin stimulation caused Isc to increase by 4.3  0.5
A/cm2 (n  17) However, subsequent addition of RPL554
failed to increase CFTR activity further and the total stimula-
tion was only about half that when RPL554 was added first.
These data indicate that larger responses are obtained with
these agents in combination; however, the enhanced response
depends on the order of exposure. Thus a combination therapy
involving VX-770 and RPL554 could provide additional ben-
efits to R117H/F508del patients although this may depend on
their order of administration and pharmacokinetics.
Exposure of R117H/F508del HBE cells to proinflammatory
cytokines does not alter the effect of PDE inhibition on CFTR-
dependent Isc. In an attempt to mimic the pathophysiological
state of CF airways, R117H/F508 HBE cells were treated with
the proinflammatory cytokine TNF- (1 ng/ml) for 24 h before
assessing the CFTR-dependent Isc in response to PDE3/4
inhibition. Pretreatment with TNF- did not significantly alter
the response to PDE inhibition after prestimulation with sub-
maximal forskolin (2 M); milrinone stimulation was negligi-
ble in control cells (0.3  0.2 A/cm2; n  3) and in
TNF--treated cells (0.01  0.02 A/cm2; P  0.05 vs.
control; n  3; Fig. 10), demonstrating that PDE3 inhibition
does not modulate CFTR activity, even when cells are in a
proinflammatory state. Similarly, in cells that had been pretreated
with TNF- and stimulated with forskolin, there was no increase
(P  0.05; n  3) in the Isc response to rolipram (2.6  0.1 vs.
1.9  0.4 A/cm2), milrinone 	 rolipram (2.0  0.4 vs. 2.2  0.1
A/cm2), and RPL554 (1.5  0.4 vs. 1.7  0.3 A/cm2) when
compared with control cells (Fig. 10).
RPL554 increases CBF in HBE cells. In addition to CFTR-
dependent anion secretion, mucocilary clearance depends on
ciliary beating, a process that is also regulated by cAMP
signaling (2, 18, 36, 55, 63). We therefore measured CBF in
WT HBE cells to assess whether it is increased by RPL554.
Treatment of cells with RPL554 for 30 min significantly
increased CBF by 2.6  0.8% at 1 min posttreatment compared
with time-matched DMSO controls (P  0.05; n  11), 8.1 
1.2% at 5 min posttreatment (P  0.001; n  11) and 10.4 
1.8% at 30 min posttreatment (P  0.001; n  11; Fig. 11).
Fig. 6. PDE3/4 inhibitors alone stimulate negligible CFTR-dependent Isc in R117H/F508del HBE cells. R117H/F508del HBE cells were isolated and cultured
as described in METHODS and Isc measurements were made in Ussing chambers. Cells were treated with DMSO or the CFTR corrector VX-809 (3 M) for 24
h before study. A: representative experiments in which Isc was measured in response to treatment with the PDE3 inhibitor milrinone (10 M apical; top left),
the PDE4 inhibitor rolipram (10 M apical; top right), milrinone and rolipram (bottom left), and RPL554 (10 M apical; bottom right). Cells were first treated
with apical amiloride (100 M) and the current was inhibited by CFTRinh 172 (10 M apical) while cells maintained functionality, demonstrated by a response
to apical ATP (100 M). B: summary of the data and how PDE inhibition compares to stimulation with a submaximal dose of forskolin (2 M) and the effect
of 24 h pretreatment with VX-809. **P  0.01, significant effect of VX-809 in forskolin-stimulated cells. Data represent means  SE; n numbers are displayed
in parenthesis.
The effect of RPL554 was almost identical to that of the
selective PDE4 inhibitor roflumilast (Fig. 11), providing evi-
dence that RPL554 increases ciliary beating and therefore is
predicted to promote mucociliary clearance in both WT and CF
patients.
DISCUSSION
By inhibiting phosphodiesterase-dependent breakdown of
cAMP, PDE3, and PDE4 inhibitors have previously been
shown to stimulate CFTR in human airway epithelial cells,
suggesting they could be a therapeutic option for the treatment
of CF. Here, we investigated the effect of RPL544, a dual
PDE3/4 inhibitor that has bronchodilator effects in asthma and
COPD patients (20), for its ability to restore CFTR function in
several cell types, including primary HBE. Firstly, we demon-
strated that although RPL554 was not able to stimulate CFTR
in CHO cells, indicative of low basal adenylyl cyclase activity,
it was able to potentiate CFTR activity when cells were
stimulated by a submaximal concentration of forskolin (Fig. 1).
These findings imply that inhibition of PDE3 and 4 in CHO
cells enhanced the increase in [cAMP]i after forskolin stimu-
lation sufficiently to further stimulate CFTR. By contrast,
RPL554 did stimulate CFTR in the bronchial epithelial cell line
CFBE under basal conditions in a dose-dependent manner (Fig.
2). Although the highest concentration of RPL554 tested was
less potent than forskolin, PDE3/4 inhibition was clearly able
to raise [cAMP]i sufficiently to activate CFTR. These results
with CFBE cells are similar to those reported for the airway
cell line Calu-3 in which PDE3 and PDE4 inhibitors induced
10–85% of the forskolin response (12). More specifically, the
fact that PDE4D has been shown to be involved in cAMP
compartmentalization (4) suggests that the effects of RPL554
may be mediated by increased cAMP levels within the CFTR
microdomain that depends on transmembrane adenylyl cyclase
(tmAC) activity. The distinct effects of RPL554 in CHO and
CFBE cells suggest CFBE cells have much higher basal tmAC
activity and consequentially cAMP turnover and highlight the
cell-type specific effects of RPL554.
We next compared the effects of the dual PDE3/4 inhibitor
RPL554 with those of the PDE3-selective inhibitor (milrinone)
and the PDE4-selective inhibitor (rolipram). CFTR-dependent
anion transport was measured in primary HBE cells from CF
patients carrying F508del/F508del or R117H/F508del al-
leles. Quantitative PCR results revealed upregulation of PDE3
Fig. 7. PDE4 inhibition stimulates CFTR-dependent Isc in R117H/F508del HBE cells after prestimulation with forskolin. R117H/F508del HBE cells were isolated
and cultured as described in METHODS and Isc measurements were made in Ussing chambers. Cells were treated with DMSO or the CFTR corrector VX-809 (3
M) for 24 h before study. A: representative experiments in which Isc was measured in response to treatment with the PDE3 inhibitor milrinone (10 M apical;
top left), the PDE4 inhibitor rolipram (10 M apical; top right), milrinone and rolipram (bottom left), and RPL554 (10 M apical; bottom right). Cells were first
treated with apical amiloride (100 M) and then stimulated with submaximal concentration of apical forskolin (2 M). The resulting Isc increase was inhibited
by CFTRinh 172 (10 M apical) while cells maintained functionality, demonstrated by a response to apical ATP (100 M). B: summary of data and how PDE
inhibition compares to stimulation with a submaximal dose of forskolin (2 M) and the effect of 24 h pretreatment with VX-809. *P  0.05, **P  0.01,
significant effect of PDE inhibitor vs. milrinone alone. Data represent means  SE; n numbers are displayed in parenthesis.
and PDE4D expression in CF cells when compared with WT
cells, but the overall level of PDE3 expression was very low
compared with PDE4D and, interestingly, PDE7A and PDE8A
(Fig. 3). In F508del/F508del cells pretreated with VX-770 and
VX-809, forskolin stimulated CFTR-dependent Isc; however,
PDE inhibitors did not cause further Isc increases suggesting
that F508del CFTR was maximally activated after forskolin
stimulation (Fig. 4). This is perhaps surprising when one
considers that the gene expression of PDE3 and PDE4D was
upregulated in F508del/F508del cells; however, it is worth
noting that mRNA abundance may not strictly be proportional
to protein expression. In noncorrected F508del/F508del cells,
forskolin failed to increase CFTR-dependent Isc and subse-
quent PDE inhibition also did not activate CFTR, demonstrat-
ing the importance of VX-809 and VX-770 therapy for these
patients. However, in the presence of PDE inhibitors, VX-770-
stimulated Isc was significantly enhanced compared with con-
trol cells, suggesting PDE inhibitors can stimulate CFTR after
potentiation by VX-770 (Fig. 5). In R117H/F508del cells, PDE
inhibition alone failed to stimulate CFTR-dependent Isc, al-
though rolipram, milrinone 	 rolipram, and RPL554 all in-
creased Isc when cells were prestimulated with forskolin. The
lack of effect of milrinone as well as similar Isc stimulations
elicited by the PDE4-selective inhibitor rolipram and the dual
PDE3/4 inhibitor RPL554 suggests PDE4 inhibition mediates
most stimulation of R117H CFTR (Figs. 6–7). This is consis-
tent with the very low PDE3 gene expression measured in these
cells and agrees with other studies that have demonstrated
PDE4 activity to be significantly higher than PDE3 activity in
HBE cells (16) and PDE4 to be the predominant regulator of
CFTR in human airway epithelia (4, 6). However, PDE3
inhibition stimulates CFTR in Calu-3 cells (12, 48) raising the
possibility that PDE regulation of CFTR differs in airway
gland and surface epithelia. The negative effects of PDE
inhibition in F508del/F508del cells compared with the positive
effects in R117H/F508del cells show that the CFTR response
to PDE inhibitors in R117H/F508del cells must be due to the
R117H allele. This highlights a difference in the regulation of
R117H CFTR and F508del CFTR since R117H CFTR is not
Fig. 8. PDE3/4 contributes to cAMP compartmentalization in R117H/F508del
HBE cells. R117H/F508del HBE cells were isolated and cultured as described
in METHODS and Isc measurements were made in Ussing chambers. A: increase
in CFTR-dependent Isc after cells were stimulated with either forskolin (2 M)
or apical adenosine (Ado; 10 M). B: further Isc increase after subsequent
inhibition of PDE3/4 using either milrinone (10 M) 	 rolipram (10 M) or
RPL554 (10 M) was also assessed. ***P  0.001, significant difference
between forskolin and adenosine. Data represent means  SE; n numbers are
displayed in parenthesis.
Fig. 10. TNF- treatment does not modulate PDE inhibitor-stimulated CFTR-
dependent Isc in R117H/F508del HBE cells. R117H/F508del HBE cells were
isolated and cultured as described in METHODS and Isc measurements were
made in Ussing chambers. Cells were treated with PBS (control) or TNF- (1
ng/ml) 24 h before the study and CFTR-dependent Isc was measured in
response to milrinone (10 M), rolipram (10 M), milrinone 	 rolipram, and
RPL554 (10 M) after cells were prestimulated with forskolin (2 M). Data
represent means  SE; n  3–4.
Fig. 9. RPL554 does not further stimulate CFTR-dependent Isc after acute treatment with VX-770 in R117H/F508del HBE cells. R117H/F508del HBE cells were 
isolated and cultured as described in METHODS and Isc measurements were made in Ussing chambers. A: representative experiments in which cells were stimulated 
with forskolin and then treated with either VX-770 (100 nM) followed by RPL554 (10 M; left) or RPL554 followed by VX-770 (right). B: increase in Isc after 
treatment with each drug either alone or in combination. **P  0.01, significant effect of RPL554 VX-770 vs. either agonist alone. Data represent means
SE; n numbers are displayed in parenthesis.
fully stimulated by forskolin and can be further modulated by
local changes in cAMP, in contrast to rescued F508del CFTR.
When responses to submaximal forskolin and apical adeno-
sine were compared in R117H/F508del HBE cells, forskolin
stimulated higher CFTR-dependent anion transport than aden-
osine (Fig. 8A). This parallels earlier findings in Calu-3 cells
using the patch-clamp technique (28). RPL554 and the com-
bination of milrinone 	 rolipram caused similar increases in Isc
regardless of whether the cells had been prestimulated with
forskolin or adenosine, indicating that PDE3/4 inhibition abol-
ished the compartmentalized nature of cAMP signaling pro-
duced by adenosine receptor stimulation. PDE4-dependent
compartmentalization of cAMP in Calu-3 airway epithelial
cells was reported by Barnes et al. (4), who showed that
inhibitors of PDE4, but not PDE3, can abolish the lateral
confinement of cAMP signals that are induced by adenosine
receptor activation. The PDE4 inhibitor rolipram also stimu-
lated CFTR when added to excised patches and augmented
adenosine-stimulated CFTR activity to levels observed during
forskolin stimulation. By contrast, Kelley et al. (32) showed
that CFTR in Calu-3 is strongly activated by the PDE3 inhib-
itor milrinone and weakly stimulated by rolipram. Similar
results were reported by Penmatsa et al. (48), who found that
the PDE3 inhibitor cilostazol stimulated CFTR more strongly
than rolipram in Calu-3 cells. They also demonstrated an
interaction between CFP-PDE3A and YFP-CFTR in HEK cells
using fluorescence resonance energy transfer (FRET) and co-
immunoprecipitated HA-PDE3A with Flag-CFTR. Although
some findings remain controversial, they reinforce the impor-
tance of PDE activity in regulating local cAMP levels in HBE
cells.
Considering that RPL554 increases forskolin-stimulated
CFTR channel activity, it was interesting to examine its effects
in the presence of VX-770, a clinically prescribed CFTR
potentiator. VX-770 binds directly to CFTR to increase chan-
nel gating and thus potentiates its activity after stimulation with
cAMP agonists (29, 66). We observed that VX-770 further
enhanced CFTR activity in cells treated with forskolin and
RPL554 (Fig. 9). Thus these findings demonstrate CFTR ac-
tivity can still be increased by CFTR potentiators, even after
forskolin and RPL554 stimulation, highlighting that gating
limits CFTR activity in the presence of cAMP and that fors-
kolin and RPL554 did not stimulate CFTR to its maximal
activity in R117H/F508 cells. However, when cells were
stimulated with forskolin and then potentiated with VX-770,
subsequent addition of RPL554 failed to further activate
CFTR. This indicates that forskolin-induced phosphorylation
of CFTR is sufficient for a maximal response to VX-770, and
once VX-770 has potentiated CFTR further increases in
[cAMP]i, due to PDE inhibition have no effect on CFTR
activity. Interestingly, when RPL554 was added first followed
by VX-770, the net Isc increase was significantly greater than
when either agonist was added alone or combined in the
reverse order. This implies that combining these two drugs
provides the highest level of CFTR stimulation although
this will likely depend on the pharmacokinetics of both com-
pounds and require administration of RPL554 before VX-770.
It is important to note that, in these studies, VX-770 was added
acutely so it remains to be seen what would happen in the clinic
under chronic dosing conditions.
CF airways are chronically inflamed, mediated by high
levels of proinflammatory cytokines, including IL-8 and
TNF- (33, 51, 56, 59). Therefore, we examined whether
CFTR-dependent anion transport in response to PDE inhibitors
was altered in cells exposed to proinflammatory cytokines.
However, 24-h treatment with TNF- did not affect the re-
sponse to PDE inhibition as only PDE4 inhibition stimulated
CFTR-dependent Isc in control and TNF--treated cells (Fig.
10). However, these data do show that the effects of RPL554
are not compromised by the presence of TNF- and therefore
support its potential therapeutic use in CF airways.
Mucociliary clearance depends on CFTR-driven fluid secre-
tion and ciliary beating; therefore, we examined the effect of
RPL554 on CBF. CBF was increased significantly, consistent
with the regulation of CBF by cAMP signaling (Fig. 11). A
similar increase in CBF was observed with roflumilast, which
is in agreement with previous findings (43). The similar in-
creases in CBF induced by roflumilast and RPL554 suggest the
response was mediated by inhibition of PDE4. Although equiv-
alent experiments were not yet performed using CF cells, since
CBF is regulated by PKA-dependent phosphorylation of dy-
nein light chains, the regulation of CBF is probably not CFTR
dependent and should be similar in CF cells.
In summary, we have demonstrated for the first time that the
PDE3/4 dual inhibitor RPL554 stimulates CFTR in well-
differentiated HBE cells from R117H/F508del and therefore
could provide therapeutic benefits to patients carrying at least
one R117H allele. The mechanism of action apparently in-
volves exclusively PDE4 and is additive with the effect of
VX-770; therefore, it may further enhance CFTR activity in
combination with VX-770. RPL554 also increased CBF in
well-differentiated HBE cells, which again was seemingly
mediated by PDE4 inhibition. These findings imply that
RPL554 would serve to improve lung function in CF patients
by 1) stimulating CFTR-dependent anion transport allowing
for mucus hydration and 2) increasing CBF to enhance muco-
ciliary clearance. Furthermore, CFTR activation causes relax-
ation of rat and human airway smooth muscle (47, 53, 67); thus
RPL554 activation of CFTR may contribute to clinical im-
provement in COPD patients through improved mucus clear-
ance by the epithelium or through airway smooth muscle
relaxation and subsequent bronchodilation.
Fig. 11. RPL554 increases ciliary beat frequency (CBF) in HBE cells. WT
HBE cells were isolated and cultured as described in METHODS and CBF was
measured using video microscopy. Cells were treated with DMSO (control),
roflumilast (1 M), or RPL554 (10 M) and the CBF was measured 1, 5, and
30 min posttreatment. *P  0.05, ***P  0.001, significant effect of RPL554
vs. DMSO; †P  0.001, significant effect of roflumilast vs. DMSO. Data
represent means  SE of 3–4 repeat experiments from 3 different patients
(n  9–11).
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